West Palm Beach, FA ; 03/16/2020
Amount Funded: $19 Million
Type: Series B
Lead Investor: MSD Partners, F1 Bio Ventues
Participating Investor(s): Individual Investors (note conversions)
Company Description: “EXUMA Biotech Corp is a private Delaware corporation formed in November 2015 with operations in West Palm Beach, Florida and international affiliates in the Cayman Islands and Shanghai, China. EXUMA leverages its globally integrated science, development and informatics teams located across multiple time zones to accelerate the design, high-throughput screening, discovery and development of Chimeric Antigen Receptor T cell (CAR-T) candidates for both solid and liquid tumor malignancies. The company is developing logic gated CAR-T platforms to advance TME-restricted cellular therapies for solid tumors, platforms that will allow for same-day, rapid point of care (rPOC) administration for solid or liquid tumors, and highly scalable systems for global therapy deployment, beginning in Asia.”
What funding will be used for: Advance new logic gated CAR-T therapies for solid tumor malignancies, further development and partnering of rapid point-of-care, same-day CAR-T platform technology.
“We are now moving forward together as one company. The timing was right for us to create a unified global platform to leverage our synergistic capabilities, which we believe will ultimately allow us to produce and deliver CAR-T products even more efficiently for the millions of people worldwide in need of cutting-edge treatments in their fight against cancer.”
-Gregory Frost, Ph. D., Chairman/CEO, EXUMA Biotech Corp.
- . EXUMA Biotech Corp. was previously known as F1 Oncology.
Data provided by respective company (unless otherwise noted) and researched by StartupsOne for accuracy.